Selecta Biosciences to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology firm specializing in tolerogenic therapies, announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022. The company will host a pre-recorded fireside chat available on September 12 at 7:00 a.m. ET, alongside one-on-one investor meetings. Selecta focuses on leveraging its ImmTOR^® platform to enhance gene therapies and treat autoimmune diseases. An archived webcast will be accessible on the company's website for further insights.

WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR^® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company’s Management will participate in a fireside chat and participate virtually in one-on-one investor meetings at the H.C. Wainwright 24^th Annual Global Investment Conference, to be held virtually and in New York, NY from September 12-14, 2022.

H.C. Wainwright 24^th Annual Global Investment Conference
Format: Pre-recorded fireside chat and one-on-one investor meetings
Date: Monday, September 12, 2022
Time: Fireside chat available at 7:00 a.m. ET
Webcast: Click Here

An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR^® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media: 
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com 

FAQ

When is Selecta Biosciences participating in the H.C. Wainwright 24th Annual Global Investment Conference?

Selecta Biosciences will participate in the conference from September 12-14, 2022.

What is the date and time of Selecta's fireside chat at the conference?

The fireside chat is scheduled for September 12, 2022, at 7:00 a.m. ET.

How can I access the archived webcast of Selecta Biosciences' fireside chat?

The archived webcast will be available in the Investors & Media section of Selecta Biosciences' website.

What is the focus of Selecta Biosciences' ImmTOR® platform?

Selecta's ImmTOR® platform focuses on developing therapies to mitigate unwanted immune responses and enhance gene therapies.

What type of therapies does Selecta Biosciences develop?

Selecta develops tolerogenic therapies for autoimmune diseases and gene therapies.